To achieve medium to long term capital growth and to provide greater returns than a deposit based savings account.
Name | % Net Assets |
---|---|
HSBC HLDGS | 7.4% |
BP | 6.3% |
GlaxoSmithKline | 5.9% |
ROYAL DUTCH SHELL | 4.7% |
VODAFONE GROUP | 4.1% |
ROYAL BANK OF SCOTLAND GROUP PLC | 3.8% |
ASTRAZENECA | 3.7% |
ROYAL DUTCH SHELL | 3.5% |
BARCLAYS | 2.9% |
HBOS | 2.6% |
Key | % Net Assets |
---|---|
HSBC HLDGS | 7.4% |
BP | 6.3% |
GlaxoSmithKline | 5.9% |
ROYAL DUTCH SHELL | 4.7% |
Other | 75.7% |
Date | 21-Nov-2024 |
---|---|
Bid | 238.10p |
Offer | 238.10p |
Currency | GBP |
Change | -0.80p |
% | -0.33% |
YTD change | 10.10p |
YTD % | 4.43% |
Fund Inception | 01/05/1995 |
---|---|
Fund Manager | Barclays Global Investors |
TER | 0.60 (19-Feb-2014) |
Minimum Investment | |
---|---|
Initial | £100 |
Additional | £100 |
Savings | £25 |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 1.00% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.04 |
You are here: research